BofA lowered the firm’s price target on Biohaven (BHVN) to $12 from $14 and keeps a Neutral rating on the shares. The firm views the company’s Q1 report as largely uneventful” and sees a balanced risk/reward at current share levels. The analyst cites Biohaven’s spend and pipeline value for the target cut.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHVN:
- Biohaven: Buy Rating Reiterated as Pipeline De‑Risking Builds Ahead of Key 2026 Readouts; $30 Price Target Maintained
- Biohaven Price Target Trimmed to $12 as Analyst Maintains Hold Amid Balanced Pipeline Upside and Financing Risks
- Biohaven Shareholders Back Board, Auditor and Executive Pay
- Biohaven files automatic mixed securities shelf
- Biohaven reports Q1 adjusted EPS (69c), consensus (76c)